Trump sets August 1 start for generic drug tariff clock
President Donald Trump announced a two-year tariff exemption for imported generic drugs starting August 1, followed by duties of up to 200%, to encourage domestic manufacturing. The policy extends previous agreements with major drugmakers like Johnson & Johnson and Merck, who committed to price cuts and investments.
*this image is generated using AI for illustrative purposes only.
President Donald Trump announced Tuesday that generic drugs imported into the U.S. will remain exempt from tariffs for two years before facing duties of up to 200%, as his administration seeks to push pharmaceutical manufacturing back to the U.S. Beginning August 1, imported generic medicines will continue to face a 0% tariff for two years before duties increase to 100% for one year and then 200%, according to a post by Trump on Truth Social.
Tariff Schedule and Objectives
Trump said the policy is designed to encourage drugmakers to relocate generic pharmaceutical manufacturing to the U.S., with companies that fail to build domestic plants during the transition period facing penalties. "This is done in order to RESHORE Generic Pharmaceutical Production into America," Trump added. Generic drugs account for more than 90% of prescriptions filled in the U.S., according to the Food and Drug Administration.
| Timeline | Tariff Rate |
|---|---|
| August 1 to Year 2 | 0% |
| Following Year | 100% |
| Subsequent Period | 200% |
Expansion of Manufacturing Strategy
The generic drug policy expands on the administration’s earlier strategy for branded and patented medicines, under which major drugmakers agreed to lower prices in exchange for temporary tariff exemptions. In December, nine drugmakers, including Bristol Myers Squibb Co., Merck & Co. Inc., Novartis AG, Amgen Inc. and GSK plc, committed to bringing U.S. drug prices more in line with those in other developed countries.
Johnson & Johnson committed to new manufacturing investments under those agreements earlier this year, while Merck pledged more than $70 billion toward domestic research and production. Trump said pharmaceutical facilities are now being built across the U.S. "at a level never seen before."
Will the two-year transition period provide sufficient time for generic drugmakers to construct the necessary domestic infrastructure?
How might these tariffs impact the cost of prescription drugs for consumers if domestic production capacity does not scale quickly enough?
What specific penalties will be imposed on companies that fail to establish domestic manufacturing plants during the transition period?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
